Life under the CABOSUN: Cabozantinib improves quality‐adjusted survival in comparison with sunitinib

Quality‐of‐life analyses such as this one for the Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (CABOSUN) help to better define the relative impact of treatments beyond dise...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2020-12, Vol.126 (24), p.5210-5212
Main Authors: Aragon‐Ching, Jeanny B., Madan, Ravi A.
Format: Article
Language:English
Subjects:
Clinical trials
Economic factors
Kidney cancer
Medical treatment
Metastases
Metastasis
quality of life
Renal cell carcinoma
Signs and symptoms
Social factors
Toxic diseases
Toxicity
tyrosine kinase inhibitors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Quality‐of‐life analyses such as this one for the Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (CABOSUN) help to better define the relative impact of treatments beyond disease progression metrics, including socioeconomics. Although there are no head‐to‐head comparisons of the recent major clinical trials demonstrating efficacy in first‐line therapy for intermediate‐ or poor‐risk metastatic renal cell carcinoma, data from quality‐adjusted time without symptoms of disease or toxicity analyses can be used to also determine potential quality‐of‐life gains and toxicity.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.33168